RESUMO
Nanoparticles bearing surface-conjugated targeting ligands are increasingly being explored for a variety of biomedical applications. The multivalent conjugation of targeting ligands on the surface of nanoparticles is presumed to enhance binding to the desired target. However, given the complexities inherent in the interactions of nanoparticle surfaces with proteins, and the structural diversity of nanoparticle scaffolds and targeting ligands, our understanding of how conjugation of targeting ligands affects nanoparticle binding remains incomplete. Here, we use surface plasmon resonance (SPR) to directly and quantitatively study the affinity and binding kinetics of nanoparticles that display small molecules conjugated to their surface. We studied the interaction between a single protein target and a structurally related series of targeting ligands whose intrinsic affinity varies over a 4500-fold range and performed SPR at protein densities that reflect endogenous receptor densities. We report that even weak small molecule targeting ligands can significantly enhance target-specific avidity (by up to 4 orders of magnitude) through multivalent interactions and also observe a much broader range of kinetic effects than has been previously reported. Quantitative measurement of how the affinity and kinetics of nanoparticle binding vary as a function of different surface conjugations is a rapid, generalizable approach to nanoparticle characterization that can inform the design of nanoparticles for biomedical applications.
Assuntos
Técnicas de Sonda Molecular , Nanopartículas/análise , Nanopartículas/química , Proteínas/metabolismo , Cinética , Ligantes , Ligação Proteica , Proteínas/química , Receptores de Superfície Celular/metabolismo , Ressonância de Plasmônio de SuperfícieRESUMO
Small-molecule inhibition of extracellular proteins that activate membrane receptors has proven to be extremely challenging. Diversity-oriented synthesis and small-molecule microarrays enabled the discovery of robotnikinin, a small molecule that binds the extracellular Sonic hedgehog (Shh) protein and blocks Shh signaling in cell lines, human primary keratinocytes and a synthetic model of human skin. Shh pathway activity is rescued by small-molecule agonists of Smoothened, which functions immediately downstream of the Shh receptor Patched.
Assuntos
Proteínas Hedgehog/metabolismo , Lactamas/farmacologia , Lactonas/farmacologia , Transdução de Sinais/efeitos dos fármacos , Células 3T3 , Animais , Descoberta de Drogas , Humanos , Queratinócitos/efeitos dos fármacos , Queratinócitos/metabolismo , Lactamas/metabolismo , Lactonas/metabolismo , Camundongos , Receptores Patched , Receptores de Superfície Celular/genética , Receptores de Superfície Celular/metabolismoRESUMO
Scavenger receptor, class B, type I (SR-BI), controls high-density lipoprotein (HDL) metabolism by mediating cellular selective uptake of lipids from HDL without the concomitant degradation of the lipoprotein particle. We previously identified in a high-throughput chemical screen of intact cells five compounds (BLT-1-5) that inhibit SR-BI-dependent lipid transport from HDL, but do not block HDL binding to SR-BI on the cell surface. Although these BLTs are widely used to examine the diverse functions of SR-BI, their direct target(s), SR-BI itself or some other component of the SR-BI pathway, has not been identified. Here we show that SR-BI in the context of a membrane lipid environment is the target of BLT-1, -3, -4, and -5. The analysis using intact cells and an in vitro system of purified SR-BI reconstituted into liposomes was aided by information derived from structure-activity relationship (SAR) analysis of the most potent of these BLTs, the thiosemicarbazone BLT-1. We found that the sulfur atom of BLT-1 was crucially important for its inhibitory activity, because changing it to an oxygen atom resulted in the isostructural, but essentially inactive, semicarbazone derivative BLT-1sc. SAR analysis also established the importance of BLT-1's hydrophobic tail. BLTs and their corresponding inactive compounds can be used to explore the mechanism and function of SR-BI-mediated selective lipid uptake in diverse mammalian experimental models. Consequently, BLTs may help determine the therapeutic potential of SR-BI-targeted pharmaceutical drugs.
Assuntos
Antígenos CD36/metabolismo , Lipoproteínas HDL/metabolismo , Receptores de Lipoproteínas/metabolismo , Tiossemicarbazonas/farmacologia , Aminas/química , Aminas/farmacologia , Transporte Biológico/efeitos dos fármacos , Linhagem Celular , Ciclopentanos/química , Ciclopentanos/farmacologia , Humanos , Metabolismo dos Lipídeos/efeitos dos fármacos , Lipoproteínas HDL/antagonistas & inibidores , Lipossomos/metabolismo , Estrutura Molecular , Ligação Proteica/efeitos dos fármacos , Receptores de Lipoproteínas/antagonistas & inibidores , Relação Estrutura-Atividade , Ressonância de Plasmônio de Superfície , Tiossemicarbazonas/síntese química , Tiossemicarbazonas/químicaRESUMO
Treatment of atherosclerotic disease often focuses on reducing plasma LDL-cholesterol or increasing plasma HDL-cholesterol. We examined in vitro the effects on HDL receptor [scavenger receptor class B type I (SR-BI)] activity of three classes of clinical and experimental plasma HDL-cholesterol-elevating compounds: niacin, fibrates, and HDL376. Fenofibrate (FF) and HDL376 were potent (IC(50) approximately 1 microM), direct inhibitors of SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI. FF, a prodrug, was a more potent inhibitor of SR-BI than an activator of peroxisome proliferator-activated receptor alpha, a target of its active fenofibric acid (FFA) derivative. Nevertheless, FFA, four other fibrates (clofibrate, gemfibrozil, ciprofibrate, and bezafibrate), and niacin had little, if any, effect on SR-BI, suggesting that they do not directly target SR-BI in vivo. However, similarities of HDL376 treatment and SR-BI gene knockout on HDL metabolism in vivo (increased HDL-cholesterol and HDL particle sizes) and structure-activity relationship analysis suggest that SR-BI may be a target of HDL376 in vivo. HDL376 and other inhibitors may help elucidate SR-BI function in diverse mammalian models and determine the therapeutic potential of SR-BI-directed pharmaceuticals.
Assuntos
Anticolesterolemiantes/farmacologia , HDL-Colesterol/metabolismo , Lipoproteínas HDL/metabolismo , Receptores de Lipoproteínas/metabolismo , Receptores Depuradores Classe B/metabolismo , Anticolesterolemiantes/síntese química , Células Cultivadas , Ácido Clofíbrico/farmacologia , Relação Dose-Resposta a Droga , Fenofibrato/farmacologia , Humanos , Receptores Depuradores Classe B/antagonistas & inibidores , Tioureia/análogos & derivados , Tioureia/síntese química , Tioureia/farmacologiaRESUMO
An epoxide derived from (-)-shikimic acid was attached to a solid support and used to synthesize over 5000 diverse small molecules. Key transformations include a Lewis acid-catalyzed epoxide opening with amines and an intramolecular Heck reaction with aryl iodides. Compounds derived from this pathway were printed onto small-molecule microarrays and screened for binding to proteins. Compounds that bound to Aurora A kinase were characterized using surface plasmon resonance.
Assuntos
Ácido Chiquímico/química , Aurora Quinases , Ciclização , Proteínas Serina-Treonina Quinases/metabolismo , Especificidade por Substrato , Ressonância de Plasmônio de SuperfícieRESUMO
Uncovering the functions of thousands of gene products, in various states of post-translational modification, is a key challenge in the post-genome era. To identify small-molecule probes for each protein function, high-throughput methods for ligand discovery are needed. In recent years, small-molecule microarrays (SMMs) have emerged as high-throughput and miniaturized screening tools for discovering protein-small-molecule interactions. Microarrays of small molecules from a variety of sources, including FDA-approved drugs, natural products and products of combinatorial chemistry and diversity-oriented synthesis, have been prepared and screened by several laboratories, leading to several newly discovered protein-ligand pairs.
Assuntos
Produtos Biológicos/química , Química Farmacêutica/métodos , Técnicas de Química Combinatória/métodos , Análise em Microsséries/métodos , Peptídeos/química , Produtos Biológicos/genética , Química Farmacêutica/tendências , Técnicas de Química Combinatória/tendências , Ligantes , Análise em Microsséries/tendências , Sondas Moleculares , Peptídeos/genética , Processamento de Proteína Pós-Traducional , Sensibilidade e EspecificidadeRESUMO
Herein we report the expanded functional group compatibility of small-molecule microarrays to include immobilization of primary alcohols, secondary alcohols, phenols, carboxylic acids, hydroxamic acids, thiols, and amines on a single slide surface. Small-molecule "diversity microarrays" containing nearly 10,000 known bioactive small molecules, natural products, and small molecules originating from several diversity-oriented syntheses were produced by using an isocyanate-mediated covalent capture strategy. Selected printed bioactive compounds were detected with antibodies against compounds of interest. The new surface of the diversity microarrays is highly compatible with approaches involving cellular lysates. This feature has enabled a robust, optimized screening methodology using cellular lysates, allowing the detection of specific interactions with a broad range of binding affinity by using epitope-tagged or chimeric fluorescent proteins without prior purification. We believe that this expanded research capability has considerable promise in biology and medicine.